Home › Chronic Lymphocytic Leukemia › Tennessee
Chronic Lymphocytic Leukemia clinical trials in Tennessee
17 studies for Chronic Lymphocytic Leukemia are looking for participants at sites in Tennessee.
Cities in Tennessee
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
RecruitingPhase 3
Ages 65 and older · All sexes · Updated Oct 2, 2026 · NCT07321652Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Ballad Health Cancer Care - Kingsport, Kingsport
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT04269902A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Tennessee Oncology Greco Hainsworth Centers For Research Chattanooga, Chattanooga
- Tennessee Oncology, Nashville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06943872A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Tennesse Oncology Chattanooga Downtown, Chattanooga
- Tennessee Oncology, Pllc Nashville, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05006716A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Tennessee Oncology, Pllc Nashville, Nashville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06973187A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Tennessee Oncology-Chattanooga ( Site 0045), Chattanooga
- Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 0031), Nashville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06136559A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- SCRI Oncology Partners, Nashville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07221500Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
- SCRI Oncology Partners, Nashville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 31, 2026 · NCT07516093Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- SCRI Oncology Partners, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07520006A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Sarah Cannon Research Institute SCRI, Nashville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05254743Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- TriStar BMT, Nashville
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Aug 6, 2026 · NCT06533579A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- The West Clinic, PLLC dba West Cancer Center, Germantown
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 19, 2026 · NCT06588478The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Baptist Clinical Research Institute, Memphis
RecruitingPhase 1/2
Ages 12 to 95 · All sexes · Updated Apr 15, 2026 · NCT04329728A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- Tennessee Oncology, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 20, 2026 · NCT04830137A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Tennessee Oncology, Nashville
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Mar 2, 2026 · NCT06876662A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Tennessee Oncology, Nashville
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Mar 2, 2026 · NCT06876649HPC Offered for PRESERVE Expansion
- Tristar Centennial Medical Center, Nashville
RecruitingObservational study
Ages 12 to 80 · All sexes · Updated Aug 28, 2025 · NCT07145411From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.